anti-BCL9 (BCL9) Antikörper

Bezeichnung:: anti-B-Cell CLL/lymphoma 9 Antikörper (BCL9)

Auf www.antikoerper-online.de finden Sie aktuell 44 B-Cell CLL/lymphoma 9 (BCL9) Antikörper von 12 unterschiedlichen Herstellern. Zusätzlich bieten wir Ihnen BCL9 Kits (7) und BCL9 Proteine (7) und viele weitere Produktgruppen zu diesem Protein an. Insgesamt sind aktuell 59 BCL9 Produkte verfügbar.

Synonyme:: 2610202E01Rik, 8030475K17Rik, A330041G23Rik, BCL9, Gm130, legless, LGS, MGC83888, xbcl9

Alle Antikörper anzeigen	Gen	GeneID	UniProt
	BCL9	77578	Q9D219
	BCL9	607	O00512
	BCL9	310704
Alle Spezies anzeigen Weitere Synonyme anzeigen

Meistgesuchte Reaktivitäten zu anti-BCL9 (BCL9) Antikörper

Wählen Sie die Spezies und Applikation aus

anti-Mouse (Murine) BCL9 Antikörper:

anti-Human BCL9 Antikörper:

anti-Rat (Rattus) BCL9 Antikörper:

Alle verfügbaren anti-BCL9 Antikörper

Sie gelangen zu unserer vorgefilterten Suche.

Verknüpfte Pathways mit anti-BCL9 Antikörper

Stem Cell Maintenance

Weitere Produktkategorien zu BCL9 Antikörper

Weitere Antikörper gegen BCL9 Interaktionspartner

Xenopus laevis B-Cell CLL/lymphoma 9 (BCL9) Interaktionspartner

Both XBcl9 and XPygo2 are required to induce supernumerary axis and dorsal gene activation in Xenopus embryos.

Mouse (Murine) B-Cell CLL/lymphoma 9 (BCL9) Interaktionspartner

Transcriptional cofactors Bcl9, Bcl9l (zeige BCL9L Antikörper) and Pygo1 (zeige PYGO1 Antikörper)/2 act independently of beta-catenin (zeige CTNNB1 Antikörper) to ensure proper enamel formation.
ARX positively regulates Wnt (zeige WNT2 Antikörper)/ beta-catenin (zeige CTNNB1 Antikörper) signaling and the C-terminal domain of ARX interacts with the armadillo (zeige PKP1 Antikörper) repeats in beta-catenin (zeige CTNNB1 Antikörper) to promote Wnt (zeige WNT2 Antikörper)/beta-catenin (zeige CTNNB1 Antikörper) signaling. In addition, we found BCL9 and P300 (zeige NOTCH1 Antikörper) also interact with ARX to modulate Wnt (zeige WNT2 Antikörper)/beta-catenin (zeige CTNNB1 Antikörper) signaling.
Study demonstrates that the Golgi resident protein GM130 (zeige GOLGA2 Antikörper) activates the spindle assembly factor TPX2 (zeige DAZL Antikörper) to nucleate microtubules around the Golgi and further captures them to couple mitotic membranes to the spindle.
Pax6 (zeige PAX6 Antikörper), the master regulator of eye development, directly activates Bcl9/9l transcription.
These results suggest a critical role of BCL9/9-2 in the Wnt (zeige WNT2 Antikörper)-mediated regulation of adult, as opposed to embryonic, myogenic progenitors.

Human B-Cell CLL/lymphoma 9 (BCL9) Interaktionspartner

High BCL9 expression is associated with cisplatin-resistance in non-small cell lung cancer.
miR (zeige MLXIP Antikörper)-1301 inhibits hepatocellular carcinoma cell migration, invasion, and angiogenesis by decreasing Wnt (zeige WNT2 Antikörper)/beta-catenin (zeige CTNNB1 Antikörper) signaling through targeting BCL9.
results from this study demonstrated that hypoxia induced BCL-9 expression in human CRC (zeige CALR Antikörper) cells mainly through HIF-1alpha (zeige HIF1A Antikörper), which could be an important underlying mechanism for increased BCL-9 expression in CRC (zeige CALR Antikörper).
SOX7 (zeige SOX7 Antikörper) inhibits oncogenic beta-catenin (zeige CTNNB1 Antikörper)-mediated transcription by disrupting the beta-catenin (zeige CTNNB1 Antikörper)/BCL9 interaction.
The authors used CRISPR/Cas9 genome engineering of Drosophila legless (lgs) and human BCL9 and B9L (zeige BCL9L Antikörper) to show that the C-terminus downstream of their adaptor elements is crucial for Wnt (zeige WNT2 Antikörper) responses.
MEF2D (zeige MEF2D Antikörper)-BCL9-positive patients had B-cell precursor immunophenotype and were characterized as being older in age, being resistant to chemotherapy, having very early relapse, and having leukemic blasts that mimic morphologically mature B-cell leukemia with markedly high expression of HDAC9 (zeige HDAC9 Antikörper).
it was demonstrated that miR218 modulated a novel molecular target and the present study provided novel insights into potential mechanisms of RCC (zeige XRCC1 Antikörper) oncogenesis.
findings indicate that BCL9 most likely does not harbor a common genetic variant that can increase the risk for schizophrenia in the Japanese population
BCL9/9L-beta-catenin (zeige CTNNB1 Antikörper) Signaling is Associated With Poor Outcome in Colorectal Cancer
BCL9 is a molecular driver of DCIS invasive progression.

BCL9 Antigen-Profil

Beschreibung des Gens

BCL9 is associated with B-cell acute lymphoblastic leukemia. It may be a target of translocation in B-cell malignancies with abnormalities of 1q21. Its function is unknown. The overexpression of BCL9 may be of pathogenic significance in B-cell malignancies.

Alternative names and synonyms associated with BCL9

B-cell CLL/lymphoma 9 L homeolog (bcl9.L) Antikörper
B-cell CLL/lymphoma 9 (BCL9) Antikörper
B cell CLL/lymphoma 9 (Bcl9) Antikörper
B-cell CLL/lymphoma 9 (Bcl9) Antikörper

2610202E01Rik Antikörper
8030475K17Rik Antikörper
A330041G23Rik Antikörper
BCL9 Antikörper
Gm130 Antikörper
legless Antikörper
LGS Antikörper
MGC83888 Antikörper
xbcl9 Antikörper

Bezeichner auf Proteinebene für BCL9

B-cell CLL/lymphoma 9 , B-cell lymphoma 9 , B-cell CLL/lymphoma 9 protein-like , b-cell CLL/lymphoma 9 protein-like , B-cell CLL/lymphoma 9 protein , B-cell lymphoma 9 protein , bcl-9 , nuclear co-factor of beta-catenin signalling , protein legless homolog

GENE ID	SPEZIES
431941	Xenopus laevis
457248	Pan troglodytes
100405208	Callithrix jacchus
100440022	Pongo abelii
100481271	Ailuropoda melanoleuca
77578	Mus musculus
607	Homo sapiens
100155378	Sus scrofa
418456	Gallus gallus
483154	Canis lupus familiaris
788729	Bos taurus
310704	Rattus norvegicus

Ausgewählte Anbieter für anti-BCL9 (BCL9) Antikörper

Haben Sie etwas anderes gesucht?

Telefon:	+1 877 302 8632
Fax:	+1 888 205 9894 (Toll-free)
E-Mail:	orders@antikoerper-online.de